Research programme: mRNA based vaccines - CureVac/GlaxoSmithKline
Latest Information Update: 06 Aug 2024
At a glance
- Originator CureVac; GlaxoSmithKline
- Developer CureVac; GSK
- Class RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Infections
Most Recent Events
- 06 Aug 2024 Preclinical trials in Infections in United Kingdom, Germany (unspecified route) prior to August 2024 (CureVac pipeline, August 2024)
- 20 Jul 2020 CureVac and GlaxoSmithKline plans clinical development for Infections
- 20 Jul 2020 CureVac and GlaxoSmithKline plans preclinical development for Infections